治療性疫苗市場規模、佔有率及成長分析（按產品、技術及地區）- 2025-2032 年產業預測

2023 年全球治療性疫苗市場規模價值為 537.1 億美元，預計將從 2024 年的 593.5 億美元成長到 2032 年的 1319.2 億美元，預測期內（2025-2032 年）的複合年成長率為 10.5%。

由於疫苗的應用越來越增強免疫反應並幫助慢性疾病患者的康復，治療性疫苗市場預計將大幅成長。慢性病盛行率的上升以及對創新疫苗研發投入的增加預計將對銷售產生正面影響。此外，人們對預防保健的認知不斷增強以及對個人化醫療的需求預計將在未來幾年進一步推動治療性疫苗的採用。然而，研發的複雜性和對療效有限的擔憂等挑戰可能會阻礙市場的發展。為了克服這些障礙，治療性疫苗公司有機會透過將其產品與各種免疫療法和精準醫療策略相結合來探索協同效應。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

治療性疫苗市場規模（按產品和複合年成長率） (2025-2032)

• 市場概況
• 成癮疫苗
• 自體免疫疾病疫苗
• 感染疾病疫苗
• 神經系統疫苗

治療性疫苗市場規模（依技術及複合年成長率） (2025-2032)

• 市場概況
• 自體疫苗​​接種
• 同源疫苗

治療性疫苗市場規模（按地區分類）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• GlaxoSmithKline plc（GSK）（United Kingdom）
• Sanofi SA（France）
• Pfizer Inc.（United States）
• Moderna, Inc.（United States）
• BioNTech SE（Germany）
• Bavarian Nordic A/S（Denmark）
• Medigene AG（Germany）
• Arbutus Biopharma Corporation（Canada）
• Inovio Pharmaceuticals, Inc.（United States）
• Dynavax Technologies Corporation（United States）
• Agenus Inc.（United States）
• Heat Biologics, Inc.（United States）
• Northwest Biotherapeutics, Inc.（United States）
• ImmunoCellular Therapeutics, Ltd.（United States）
• Advaxis, Inc.（United States）
• OncoSec Medical Incorporated（United States）
• Vical Incorporated（United States）
• Celldex Therapeutics, Inc.（United States）
• Altimmune, Inc.（United States）

結論和建議

Global Therapeutic Vaccines Market size was valued at USD 53.71 billion in 2023 and is poised to grow from USD 59.35 billion in 2024 to USD 131.92 billion by 2032, growing at a CAGR of 10.5% during the forecast period (2025-2032).

The therapeutic vaccine market is poised for significant growth, driven by the increasing application of these vaccines in enhancing immune response and aiding recovery in chronic disease patients. The rising prevalence of chronic illnesses, coupled with escalating investments in the research and development of innovative vaccines, is anticipated to positively impact sales. Additionally, the growing awareness of preventive healthcare and the demand for personalized medicine are expected to further boost therapeutic vaccine adoption in the coming years. However, challenges such as the complexity of R&D and concerns over limited efficacy may hinder market development. To navigate these obstacles, therapeutic vaccine companies have the opportunity to explore synergies by integrating their offerings with various immunotherapies and precision medicine strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Therapeutic Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Therapeutic Vaccines Market Segments Analysis

Global Therapeutic Vaccines Market is segmented by Products, Technology and Region. Based on Products, the market is segmented into Addiction Vaccines, Autoimmune Disease Vaccines, Infectious Disease Vaccines and Neurological Disease Vaccines. Based on Technology, the market is segmented into Autologous vaccines and Allogeneic vaccines. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Therapeutic Vaccines Market

The rising prevalence of infectious and chronic diseases globally has heightened awareness of the importance of preventive healthcare among the population. This growing consciousness is projected to positively influence the market for therapeutic vaccines, as more individuals recognize the value of vaccination in preventing illness. As a result, the demand for innovative therapeutic vaccine solutions is expected to surge, driving sales and expanding market opportunities. This shift in perspective towards proactive health measures underscores the critical role that therapeutic vaccines play in enhancing public health outcomes and addressing global health challenges.

Restraints in the Global Therapeutic Vaccines Market

The Global Therapeutic Vaccines market faces significant constraints due to the extensive and demanding approval and testing protocols that these vaccines must navigate before being authorized for patient use worldwide. This intricate and time-consuming process can considerably delay the entry of therapeutic vaccines into the market, hindering the overall growth potential of the industry. As a result, the lengthy timeline from development to market availability can create obstacles for companies, stalling innovation and limiting the timely delivery of potentially life-saving treatments to patients in need across the globe.

Market Trends of the Global Therapeutic Vaccines Market

The Global Therapeutic Vaccines market is witnessing a significant shift towards the integration of vaccines within immunotherapy frameworks, aimed at enhancing treatment efficacy for cancer patients. Vendors are increasingly focusing on developing innovative products that tailor immune responses to specific tumor types, thereby optimizing therapeutic outcomes. This trend reflects a growing recognition of the importance of personalized immunotherapy, where therapeutic vaccines are designed to modify and strengthen the body's immune system against cancer more effectively. As research and clinical applications advance, this strategic alignment is expected to drive substantial growth in the therapeutic vaccines sector, positioning it as a key component in the fight against cancer.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Therapeutic Vaccines Market Size by Products & CAGR (2025-2032)

• Market Overview
• Addiction Vaccines
• Autoimmune Disease Vaccines
• Infectious Disease Vaccines
• Neurological Disease Vaccines

Global Therapeutic Vaccines Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Autologous vaccines
• Allogeneic vaccines

Global Therapeutic Vaccines Market Size & CAGR (2025-2032)

• North America (Products, Technology)
  • US
  • Canada
• Europe (Products, Technology)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Products, Technology)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Products, Technology)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Products, Technology)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bavarian Nordic A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medigene AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arbutus Biopharma Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agenus Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heat Biologics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Northwest Biotherapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ImmunoCellular Therapeutics, Ltd. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advaxis, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OncoSec Medical Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vical Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celldex Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Altimmune, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations